Pfizer upgrades guidance for sales of covid-19 vaccine
The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Pfizer is upgrading this year's guidance for sales connected to the company's covid-19 vaccines from USD 26bn to USD 33.5bn, according to the firm's Q2 report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sweden phases out AstraZeneca's covid-19 vaccine
For subscribers
Pfizer and Biontech expand study of vaccines for children
For subscribers
